Plasma Rich in Growth Factor (PRGF) Therapy for Endometrial Receptivity: A Promising Approach in In vitro...

This case study involved a 28-year-old woman with primary infertility, chronic abnormal vaginal bleeding, recurrent miscarriages, and uterine polyps. After undergoing hysteroscopic polypectomy to remove the polyps, plasma rich in growth factors (PRGF) therapy was administered to enhance endometrial thickness. Following the therapy, the endometrial thickness increased to 7 mm, leading to successful implantation and a positive pregnancy outcome. PRGF therapy was integrated into the in vitro fertilization (IVF) process, including ovum pickup, intracytoplasmic sperm injection (ICSI), and embryo transfer. PRGF releases growth factors, such as platelet-derived growth factor and transformation growth factor (TGF-β1), which play key roles in repairing endometrial tissue, promoting cell proliferation, and enhancing the function of primary cells involved in tissue regeneration. Although the short-term results in this case are promising, further research is necessary to investigate the long-term effects of PRGF therapy on IVF outcomes, including implantation success, biochemical pregnancies, and ongoing pregnancies. PRGF therapy shows promise as a complementary treatment in IVF protocols, particularly for patients with thin endometrial linings or uterine polyps. It offers a safe, minimally invasive, and cost-effective approach to improving endometrial receptivity and enhancing IVF success rates. However, further studies are needed to validate its long-term efficacy and its role in improving overall reproductive outcomes.